Evidence map›Paper›PMID 37535254›Full record

ReviewCurrent treatment options in oncology2023

Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?

Yan Peng, Hongxiang Yan, Wuxuan Mei, Pengfei Zhang, Changchun Zeng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan PengDepartment of Obstetrics, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.
Hongxiang YanDepartment of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.
Wuxuan MeiXianning Medical College, Hubei University of Science and Technology, Xianning, 437100, China.
Pengfei ZhangDepartment of Medical Laboratory, Shenzhen Longhua District Central Hospital, Guangdong Medical University, Shenzhen, 518110, China.
Changchun ZengDepartment of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China. zengchch@glmc.edu.cn.ORCID 0000-0002-9489-0627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementCombining immunotherapy and radiotherapy as a treatment strategy for cervical cancer has attracted increasing attention. The primary objective of this review is to provide an up-to-date summary of the knowledge regarding the combined use of radiotherapy and immunotherapy for treating cervical cancer. This review discusses the biological rationale combining immunotherapy with radiotherapy in a clinical setting and presents supporting evidence for the combination strategy based on both safety and effectiveness data. Additionally, we discuss the potential and challenges of combining radiotherapy and immunotherapy in clinical practice.

Indexed as

Uterine Cervical NeoplasmsCombined Modality TherapyFemaleHumansImmunotherapyCervical cancerImmune checkpoint inhibitorsImmunotherapyRadiotherapy

Identifiers

PMID37535254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.